Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib in relapsed/refractory myelofibrosis
NCT05279001Phase 1Recruiting
- Sponsor
- Zelgen
- Start
- Jul 2024
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of jaktinib in myelofibrosis (MF), sponsored by Zelgen. Primary endpoints: Safety of jaktinib hydrochloride tablets at 24 weeks and Dose-limiting toxicities at 28 days. Started Jul 2024; status: recruiting.
02
Drugs
jaktinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT05279001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279001.